Meeting NewsVideo

VIDEO: Eyenovia’s MicroStat shows positive phase 3 data

SAN FRANCISCO — Michael Rowe, vice president of marketing for Eyenovia, discusses results of the MIST-1 trial of MicroStat, a fixed combination of phenylephrine 2.5% and tropicamide 1%, and demonstrates how Eyenovia’s OpteJet technology works at the Glaucoma 360: New Horizons Forum.

SAN FRANCISCO — Michael Rowe, vice president of marketing for Eyenovia, discusses results of the MIST-1 trial of MicroStat, a fixed combination of phenylephrine 2.5% and tropicamide 1%, and demonstrates how Eyenovia’s OpteJet technology works at the Glaucoma 360: New Horizons Forum.

    See more from Glaucoma 360 New Horizons Forum